Compare · CYAN vs MNMD
CYAN vs MNMD
Side-by-side comparison of Cyanotech Corporation (CYAN) and Mind Medicine (MindMed) Inc. (MNMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYAN and MNMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MNMD has more recent analyst coverage (16 ratings vs 0 for CYAN).
- Company
- Cyanotech Corporation
- Mind Medicine (MindMed) Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 16
Cyanotech Corporation
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest CYAN
- SEC Form 15-12G filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- Amendment: SEC Form SC 13E3/A filed by Cyanotech Corporation
- SEC Form SC 13E3 filed by Cyanotech Corporation
- SEC Form 10-Q filed by Cyanotech Corporation
- Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
- SEC Form 4 filed by CFO, VP Fin & Admin, Treasurer Miyashiro Jennifer A.S.
- SEC Form 3 filed by new insider Miyashiro Jennifer A.S.
- Director Mulder David M was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 33% to 203,468 units (SEC Form 4)
- Director Vied David L was granted 50,000 units of Cyanotech Corporation Common Stock, increasing direct ownership by 29% to 225,138 units (SEC Form 4)
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits